drugset / Trial / NCT00414206
Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).
Timeline
- Start
- 2007-03
- Primary completion
- 2009-06
- Completion
- 2009-09
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mecamylamine | Small molecule | 0.3 % | Other |
| Comparator | Mecamylamine | Small molecule | 1 % | Other |